Introduction: Fms-related tyrosine kinase 3 (FLT3) mutation, which is considered a poor prognostic marker, is identified in 25%-45% of patients with acute myeloid leukemia (AML), and nucleophosmin (NPM1) mutation, which predicts a favorable outcome in the absence of FLT3 mutation, has been identified in approximately 35% of patients with AML. The relevance of these mutations to induction chemotherapy (IC) outcomes in AfricanAmerican patients has not been studied. Materials and Methods: Twenty consecutive cases of AML were identified and their records reviewed for clinical and laboratory data, treatment, and its outcomes. Data for karyotypic analysis, fluorescent in situ hybridization studies, and mutational analysis for FLT3 and NPM1 (performed on bone marrow) were collected.
Results: FLT3 mutation was present in six of 20 AML patients, and NPM1 mutation was present in four of 20 AML patients. Thirteen of the twenty patients did not achieve remission after induction chemotherapy. The four (4/6) patients with sole FLT3 mutation were unresponsive to IC irrespective of favorable karyotype t(8;21) in a patient, and the other two (2/6) patients with additional NPM1 mutation showed complete response to IC. Of the 14 patients negative for FLT3 mutation, the two positive for NPM1 mutation showed complete response to IC in spite of complex karyotypes. Of the patients (12) negative for both FLT3 and NPM1 mutations, three patients showed complete response to IC. Conclusion: In general, African-American patients had poor response to IC. All patients with NPM1 mutation had complete response to IC. Patients with FLT3 mutation but without NPM1 mutation were all unresponsive to IC, while those with both FLT3 and NPM1 mutations had complete response to IC and have remained in remission. Contrary to prevailing concept, we found NPM1 mutation to be associated with favorable outcome to IC even in patients with positive FLT3. Background: Programmed cell death ligand 1 (PD-L1) is a cell surface glycoprotein that down-regulates the immune responses through binding to its inhibitory receptor (PD-1) on T cells. Primary effusion lymphoma (PEL) is an uncommon, large B-cell non-Hodgkin lymphoma associated with immunosuppression. Given the lack of literature on PD-L1 expression in PEL and potential targetable immunotherapy, we evaluated PD-L1 expression in PEL with clinical correlation. Design: Seven cases of PEL with both tissue and clinical data were available for review. IHC was performed using monoclonal antibodies against PD-L1 (SP142) and PD1 (NAT105). PD-L1 immunoreactivity was scored in the neoplastic cells (nPD-L1) as percentage (%) of neoplastic cells and was stratified into low (< 5%) and high expression (≥5%) groups. We also scored PD-L1 expression in the stromal cells (sPD-L1) as the percentage of cells staining in tumor region. PD-1 was scored as the number of positive T-cells per high power field (HPF). Results: All subjects were men. The median age was 64 years. Specimen types included five pleural or pericardial fluids, and two extracavitary lymph nodes. A higher expression of nPD-L1 was observed only in two cases, both extracavitary lesions. nPD-L1 positivity showed no significant relationship in regard to age, HIV or EBER status, PD-1 on T cells, or stromal/macrophage PD-L1 percentage (range 2%40%, median 5%). Over a median follow-up of 1.8 months (range 0.53-80.10 months), all two patients with a higher nPD-L1 expression died, whereas three of five patients died in the low nPD-L1 group (P > .05). Conclusion: This is the first report to describe PD-L1 expression in both neoplastic cells and tumor infiltrating stroma/macrophages in PEL with clinicopathologic correlation. Our observations suggest that induction of local immunosuppression by the PD-1/PD-L1 pathway may differ between cavitary and extracavitary disease. Further studies are needed to validate these results. Plasmacytosis is one of the most common histologic findings in the lymph node biopsy evaluation. We retrospectively reviewed lymph node biopsy cases from our institution. We analyzed a large series of lymphadenopathy cases to compare histologic, immunophenotypic, and clinical features of benign reactive plasmacytosis vs malignant plasma cell neoplasms. We identified 106 cases that showed features of follicular hyperplasia with interfollicular plasmacytosis. These cases were morphologically subdivided into four groups with additional specific findings including florid reactive follicular hyperplasia (FRFH), marginal zone hyperplasia (MZH), Castlemanlike morphology, and a diffuse pattern with cytological atypia. The most common etiology was FRFH with interfollicular plasmacytosis and was observed in a majority of cases (68%). Most of these cases were accompanied with several reactive immunological abnormalities (rheumatoid arthritis, SLE, Epstein-Barr virus, or human immunodeficiency virus infections, IgG4 disease, and plasma cell variant of Castleman disease). Of all the cases, 12 also presented with systemic polytypical plasmacytosis, which was found to be associated with currently ill-defined clinicopathological entities that we categorized as autoimmune diseases. Of note, the cases with IgG4 disease exhibited patchy, uneven distribution of IgG4-positive plasma cells with expansion of intrafollicular plasma cells and perifollicular fibrosis. The cases with cytological atypia (32%) and clonality of restrictive immunoglobulin light chain either by flow cytometry, immunohistochemistry, or in situ hybridization were further classified as plasmacytoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, diffuse large B-cell lymphoma with plasmacytic differentiation or plasmablastic lymphoma. Histologic identification of immature plasma cell differentiation, mitotic figures, Dutcher body, immunophenotypical aberrancy by flow cytometry in the plasma cells (CD19-, CD56+, CD33+, or CD117+) are important features for distinguishing plasma cell tumors from reactive conditions. Therefore, it is important to identify malignant clonal plasmacytosis by integration of morphologic, immunophenotypic, immunofixation, radiologic, and cytogenetic findings.
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PD-L1 Expression in Primary Effusion
The Challenge of Necrotic Tissue for Lymphoma Work-Up
Fadi Alakeel, Louis DePalma, MD, Xiaojun Wu, MD, PhD; George Washington University Hospital, Washington, DC Introduction: Lymph node necrosis/infarction is not a rare event and may be the presenting manifestation for malignant lymphoma. However, accurate diagnosis is difficult and sometimes impossible when biopsy tissue has extensive necrosis. Moreover, there is conceptual belief that immunohistochemistry studies are not sensitive nor specific for the necrotic tissue. The purpose of this study is to emphasize the importance of methodical analysis of the suboptimal/necrotic tissue using a combined histologic and limited immunohistochemistry study that can aid in establishing lymphoma diagnosis. Design: Lymph node biopsies of three adult cases showing extensive coagulative necrosis/infarction. Histomorphologic evaluation of paraffin-embedded tissue together with immunohistochemistry studies is performed. Results: Cases 1 and 2 show small patchy areas of small lymphocyte-dominant infiltrate in a background of extensive fibrosis and necrosis. Case 3 shows coagulative necrosis with peripheral reactive appearing lymph node tissue. All cases show preservation of CD20 in a diffuse pattern and scattered CD3 positive T-lymphocytes in necrotic areas. The residual viable lymphocytic infiltrate shows atypical immunophenotypes, such as monotypic light chain expression in a minute plasmablastic focus (case 1), CD10-/BCL6+/MUM1+ in small aggregates of atypical large lymphocytes (case 2) and mixed reactive and atypical lymphocytes (case 3). Subsequent biopsies performed for cases 2 and 3 at different intervals showed diffuse large B-cell lymphoma. Conclusion: The work-up for infarcted lymph node is challenging because of the suboptimal histomorphologic evaluation. A diffuse sheet of CD20 reactivity in monotonous appearing ghost cells with scattered T-lymphocytes is very suggestive of necrotic lymphoma. Additional immunohistochemical studies to characterize the background
